The Compound — Editorial
Why peptides matter
Ozempic was not a weight loss drug. It was a proof of concept — evidence that a peptide could reshape a $50 billion market almost overnight. The same dynamic is beginning across the broader category, and most people haven't noticed yet.
Ozempic is a peptide. Specifically, it's a modified version of GLP-1, a hormone your gut already produces to signal fullness. Novo Nordisk added a fatty acid chain to extend its half-life from minutes to a week, ran it through clinical trials, and the result was approximately 1,000 times more potent than the body's natural version. Within eighteen months of entering public consciousness, the drug class generated $71 billion in annual revenue and rearranged the pharmaceutical industry.
But semaglutide is one peptide. There are hundreds of others. And the pattern that played out with GLP-1s — from fringe to clinical to mainstream — is starting to repeat across the category.
The FDA gap is an incentive problem
The standard objection is regulatory: if these compounds worked, they'd be approved. That reasoning conflates two different questions. The FDA approval process answers "is this drug safe and effective?" well. It answers "are there safe and effective compounds that nobody has financial incentive to trial?" poorly.
Running a Phase III trial costs hundreds of millions of dollars. That investment only makes sense if you can patent the result. Many peptides are naturally occurring or have been in the public domain for decades — so the economics don't work. GHK-Cu has been studied since the 1970s. Thymosin alpha-1 is an approved pharmaceutical in 35+ countries. The research exists. The trials don't, because there's no patent to protect the return.
Semaglutide illustrates the other side of this. GLP-1 was known and studied for roughly twenty years before Ozempic launched. Novo patented a modification, funded the trials, and brought it to market. The molecule didn't change. The economics did.
How we got here
The compounds worth knowing
Most evidence below is preclinical — animal studies and mechanistic research. Human RCT data is limited for non-GLP-1 compounds. That's context, not dismissal.
GHK-Cu
The longest research track record of any compound in this category — data going back to the 1970s. Central role in wound healing and collagen production. Some evidence suggests effects on aging-related gene expression. Clean safety profile. Approved for cosmetic use and listed in high-end skincare products, which is a reasonable proxy for how established the mechanism is.
Thymosin alpha-1
The most institutionally validated non-GLP-1 peptide — an approved pharmaceutical drug in over 35 countries, used clinically for hepatitis B, cancer immunotherapy support, and chronic infections. If the standard objection is "no evidence," thymosin alpha-1 is the clearest rebuttal.
Semaglutide, Tirzepatide, Retatrutide
Semaglutide and tirzepatide are FDA-approved, well-characterized, and accessible through telehealth programs. Retatrutide — a triple-receptor agonist in Phase III — showed ~24% weight loss at 48 weeks in Phase II data. The pipeline behind these compounds is deep. This is the most actionable tier for most people.
What to actually do
For most people, the right first step is a GLP-1 program through a licensed telehealth provider. The evidence is solid, access is straightforward, and the results are well-characterized. That's the highest-confidence move in this space right now.
For the broader longevity category, the most important thing is finding a physician with actual peptide experience — someone who reviews bloodwork, knows the interactions, and has real protocols. They exist in growing numbers and many work via telemedicine. Get baseline labs before starting anything. Change one variable at a time.
The strongest case against
In July 2025, Eric Topol — cardiologist, researcher, and one of the most widely-read science writers in medicine — published a detailed critique of the peptide space in his Substack Ground Truths (200,000+ subscribers). His conclusion: the evidence base for non-GLP-1 peptides is essentially animal studies, adverse effects are real, and the demand is driven more by influencer culture than data.
His arguments deserve honest responses rather than dismissal.
"No evidence from randomized trials in humans."
Largely true — but the reason matters.
The RCT gap is real. What Topol doesn't address is why it exists. FDA trials cost hundreds of millions of dollars on molecules you can't patent. Thymosin alpha-1 — which was patented — is approved in 35+ countries. The compounds with patent protection got trials. The rest didn't. That's an incentive problem, not a safety verdict. The animal-to-human translation is still genuinely uncertain, and some of these may not work as claimed. That's worth saying clearly.
"Adverse effects aren't trivial."
This deserves a genuine concession.
Topol is right. Certain compounds carry real risk signals from the same animal models that show purported benefits. Anyone with a cancer history or predisposition should approach these compounds with explicit physician guidance. This is also why sourcing through physician-supervised compounding pharmacies matters — the risk profile is meaningfully different from unregulated grey market vendors, where impurity rates have tested as high as 86%.
"Anyone can get in the business — it's completely unregulated."
True, and it's part of why this site exists.
This is Topol's strongest practical point and we agree with it. The grey market sourcing problem is real — and it's collapsing under FDA enforcement. The correct response isn't to avoid peptides; it's to direct people toward legitimate channels: 503A/503B compounding pharmacies, licensed telehealth providers, physician oversight. That's exactly what this site is for.
The information gap between people who understand this space and people who don't is large. The window of broad, affordable access that exists right now may not exist in two years. The peptide revolution is already here. Most people just haven't noticed yet.